Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R10 | Q9NYW0 | 2/20 | 0.67 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | GLRA1 | P23415 | 15/20 | 0.54 |
| ▸ | GLRB | P48167 | 15/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | SCN1A | P35498 | 1/20 | 0.51 |
| ▸ | TAS2R46 | P59540 | 1/20 | 0.51 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.51 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Brucine SCHEMBL1748414 | 1.00 | TAS2R10 (0.67) | TAS2R10CHRM1SMN1; SMN2GLRA1GLRB | |
| Brucine SCHEMBL5592247 | 0.89 | TAS2R10 (0.69) | TAS2R10CHRM1SMN1; SMN2GLRA1GLRB | |
| Brucine SCHEMBL7546669 | 0.82 | TAS2R10 (0.94) | TAS2R10CHRM1SMN1; SMN2GLRA1GLRB | |
| Brucine SCHEMBL14029321 | 0.82 | TAS2R10 (1.00) | TAS2R10CHRM1SMN1; SMN2GLRA1GLRB | |
| Brucine SCHEMBL10307298 | 0.82 | TAS2R10 (1.00) | TAS2R10CHRM1SMN1; SMN2GLRA1GLRB | |
| Brucine SCHEMBL7753865 | 0.81 | TAS2R10 (0.84) | TAS2R10CHRM1SMN1; SMN2GLRA1GLRB | |
| Brucine SCHEMBL6794678 | 0.81 | TAS2R10 (0.98) | TAS2R10CHRM1SMN1; SMN2GLRA1GLRB | |
| Brucine SCHEMBL31317695 | 0.81 | TAS2R10 (0.98) | TAS2R10CHRM1SMN1; SMN2GLRA1GLRB | |
| Brucine SCHEMBL6233075 | 0.81 | TAS2R10 (0.98) | TAS2R10CHRM1SMN1; SMN2GLRA1GLRB | |
| Brucine SCHEMBL524833 | 0.81 | TAS2R10 (0.98) | TAS2R10CHRM1SMN1; SMN2GLRA1GLRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910299-B1 | SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | ESTEVE LABOR DR (ES) | 2011-09-07 | — | — | EP | disclosed |
| US-7968582-B2 | 5(S)-substituted pyrazoline compounds, their preparation and use as medicaments | LABOROTORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-06-28 | — | — | US | disclosed |
| EP-1946777-A1 | Substituted pyrazoline for preventing weight gain | Laboratorios del Dr. Esteve S.A. (ES) | 2008-07-23 | — | — | EP | disclosed |
| EP-1946778-A1 | Active substance combination for the treatment of diabetes | Laboratorios del Dr. Esteve S.A. (ES) | 2008-07-23 | — | — | EP | disclosed |
| EP-1944293-A1 | Alpha-Polymorph of a substituted pyrazoline, its preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2008-07-16 | — | — | EP | disclosed |
| EP-1944296-A1 | Amorphous phase of a substituted pyrazoline, its preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2008-07-16 | — | — | EP | disclosed |
| EP-1944294-A1 | Gamma-polymorph of a substituted pyrazoline, its preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2008-07-16 | — | — | EP | disclosed |
| EP-1944295-A1 | Non-racemic mixtures of (R)-N-piperidinyl-5-(4-chlorophenyl)1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxamide and (S)-N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxamide | Laboratorios del Dr. Esteve S.A. (ES) | 2008-07-16 | — | — | EP | disclosed |
| EP-1910332-A2 | SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | Laboratorios del Dr. Esteve S.A. (ES) | 2008-04-16 | — | — | EP | disclosed |
| EP-1910299-A1 | SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | Laboratorios del Dr. Esteve S.A. (ES) | 2008-04-16 | — | — | EP | disclosed |
| EP-1757587-A1 | Substituted pyrazoline compounds, their preparation and use as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-02-28 | — | — | EP | disclosed |
| WO-2007009702-A2 | SUBSTITUTED PYRAZOLINE COMPOUNDS, HAVING PREDETERMINED STEREOCHEMISTRY, FOR REDUCING TRIGLYCERIDES IN BLOOD | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007009686-A2 | SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007009695-A1 | SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-25 | — | — | WO | disclosed |
| EP-1746090-A1 | Sustituted pyrazoline compounds, having predetermined stereochemistry, for reducing triglycerides in blood | Laboratorios del Dr. Esteve S.A. (ES) | 2007-01-24 | — | — | EP | disclosed |
| US-20070015811-A1 | 5(S)-Substituted Pyrazoline Compounds, their Preparation and Use as Medicaments | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-01-18 | — | — | US | disclosed |
| US-20070015810-A1 | 5(R)-Substituted Pyrazoline Compounds, their Preparation and Use as Medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-01-18 | — | — | US | disclosed |
| EP-1743892-A1 | Substituted pyrazoline compounds, their preparation and use as medicaments | Laboratorios del Dr. Esteve S.A. (ES) | 2007-01-17 | — | — | EP | disclosed |
| EP-1743889-A1 | Sustituted pyrazoline compounds, having predetermined stereochemistry, for reducing triglycerides in blood | Laboratorios del Dr. Esteve S.A. (ES) | 2007-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015810-A1 | 5(R)-Substituted Pyrazoline Compounds, their Preparation and Use as Medicaments | CYP3A5, P2RX5, PIR | TAS2R10 1758/4885CHRM1 1013/4885SMN1; SMN2 4412/4885 |
| US-20070015811-A1 | 5(S)-Substituted Pyrazoline Compounds, their Preparation and Use as Medicaments | CYP3A5, P2RX5, PPIP5K2 | TAS2R10 2098/4885CHRM1 1114/4885SMN1; SMN2 4127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.